ANKRD22 is a novel therapeutic target for gastric mucosal injury

Biomed Pharmacother. 2022 Mar:147:112649. doi: 10.1016/j.biopha.2022.112649. Epub 2022 Jan 17.

Abstract

Ankyrin repeat domain 22 (ANKRD22) is a nuclear-encoded mitochondrial membrane protein that is highly expressed in normal gastric mucosal epithelial cells and activated macrophages. As a regulator of mitochondrial Ca2+, ANKRD22 could help repair damaged gastric mucosa by promoting the mobilization of LGR5+ gastric epithelial cells via the upregulation of Wnt/β-catenin pathway activity in a mouse model. Furthermore, the inhibition of ANKRD22 alleviated the macrophage activation-mediated inflammatory response by reducing the phosphorylation of nuclear factor of activated T cells (NFAT). ANKRD22 plays a significant role in the repair of gastric mucosal damage and may become an ideal novel target for the treatment of gastric mucosal injury. However, there is no systematic introduction to ANKRD22 targeting. Therefore, we wrote this review to elaborate the functional mechanism of ANKRD22 in gastric mucosal injury and to analyze its potential application value in clinical therapy.

Keywords: ANKRD22; Ca(2+); Epithelial stem cells; Gastric mucosal injury; Inflammation; Mitochondria.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers
  • Calcium Channels / drug effects
  • Down-Regulation
  • Epithelial Cells / drug effects
  • Gastric Mucosa / drug effects*
  • Gastric Mucosa / injuries*
  • Gastric Mucosa / pathology*
  • Inflammation Mediators / metabolism
  • Membrane Proteins / metabolism*
  • Membrane Proteins / pharmacology*
  • Mice
  • Receptors, G-Protein-Coupled / drug effects
  • Stem Cells / drug effects
  • Wnt Signaling Pathway / drug effects

Substances

  • ANKRD22 protein, human
  • Biomarkers
  • Calcium Channels
  • Inflammation Mediators
  • Membrane Proteins
  • Receptors, G-Protein-Coupled